- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alivus Life Sciences Ltd (ALIV)
Track the Alivus Life Sciences share price today and view real-time ALIV share price data, including charts, technicals, and key financials. View the ALIV premarket stock price ahead of the market session or assess the after hours quote. Explore ALIV stock price movements, trading volume, and market activity across the NSE exchange.
What Is the Alivus Life Sciences Stock Price Today?
The Alivus Life Sciences stock price today is 1,369.00.
What Is the Stock Symbol for Alivus Life Sciences?
The stock symbol for Alivus Life Sciences is ""ALIV.""
What Stock Exchange Does Alivus Life Sciences Trade On?
Alivus Life Sciences is listed and trades on the NSE stock exchange.
Is Alivus Life Sciences a Good Stock to Buy?
Determining whether Alivus Life Sciences or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALIV quote. (ISIN: INE03Q201024)
What Is the Alivus Life Sciences Stock Price Today?
The Alivus Life Sciences stock price today is 1,369.00.
What Is the Stock Symbol for Alivus Life Sciences?
The stock symbol for Alivus Life Sciences is ""ALIV.""
What Stock Exchange Does Alivus Life Sciences Trade On?
Alivus Life Sciences is listed and trades on the NSE stock exchange.
Is Alivus Life Sciences a Good Stock to Buy?
Determining whether Alivus Life Sciences or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALIV quote. (ISIN: INE03Q201024)
1,369.00
-29.70(-2.12%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,356.30
1,416.60
52 wk Range
819.00
1,418.00
ALIV is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,356.301,416.60
52 wk Range
819.001,418.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.36%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.36%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
ALIV Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
1,358.75
Downside
-0.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 1,358.75
(-0.75% Downside)
Alivus Life Sciences Ltd Earnings Call Summary for Q1/2027
- Q1 revenue rose 6.4% YoY to INR 640 crores; EBITDA margin expanded 650 bps to 36.6% despite 52.6% drop in GPL sales
- Non-GPL business surged 26.5% driven by new launches; gross margin improved 510 bps to 60.2% on favorable product mix
- Company maintained FY 2027 revenue growth guidance of 10%-12%, expecting stronger H2 performance with margin target of 30%-32%
- Alivus remains debt-free with INR 880 crores cash; capacity expansions at Dahej and Ankleshwar on track to support growth
- Pipeline includes 29 high-potent APIs targeting $82B market; patent expiries begin late 2027 with commercialization in FY 2028
Last Updated: 31/07/2026, 02:56 pm
Read Full TranscriptEarnings
Latest Release
30/07/2026
EPS / Forecast
13.00 / --
Revenue / Forecast
6.4B / 6.68B
Compare ALIV to Peers and Sector
Metrics to compare | ALIV | Peers Peers - average of corresponding metrics from companies closely matching ALIV: CAPLIPOINT, GLAND, SUPRIYA, DIVISLAB, 603456 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALIVPeersSector |
|---|---|---|---|---|
P/E Ratio | 28.2x | 32.9x | −0.3x | |
PEG Ratio | 1.31 | 0.86 | 0.00 | |
Price/Book | 5.1x | 4.5x | 2.6x | |
Price / LTM Sales | 6.6x | 7.0x | 3.1x | |
Upside (Analyst Target) | −2.4% | 11.2% | 48.5% | |
Fair Value Upside | Unlock | 2.2% | 6.3% | Unlock |
Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, urology, and pain management, as well as anti-fungal, anti-histaminic, anti-acne, anti-emetics immunomodulators, anti-ulceratives, immunosuppressant, respiratory agent, ophthalmologic agent, anti-spasmodic, and urology. The company also provides contract development and manufacturing comprising process development, analytical development and support, and API and intermediate manufacturing; and research and development, intellectual property, quality and compliance, customer experience, regulatory support. In addition, it exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited operates as a subsidiary of Nirma Limited.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Alivus Life Sciences (ALIV) Stock Price Today?
The Alivus Life Sciences stock price today is 1,369.00 INR.
What Stock Exchange Does Alivus Life Sciences Trade On?
Alivus Life Sciences is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Alivus Life Sciences?
The stock symbol for Alivus Life Sciences is "ALIV."
Does Alivus Life Sciences Pay Dividends? What’s The Current Dividend Yield?
The Alivus Life Sciences dividend yield is 0.36%.
What Is the Alivus Life Sciences Market Cap?
As of today, Alivus Life Sciences market cap is 168.03B INR.
What Is Alivus Life Sciences's Earnings Per Share (TTM)?
The Alivus Life Sciences EPS (TTM) is 49.03.
When Is the Next Alivus Life Sciences Earnings Date?
Alivus Life Sciences will release its next earnings report on 05/11/2026.
From a Technical Analysis Perspective, Is ALIV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Alivus Life Sciences Stock Split?
Alivus Life Sciences has split 0 times.
How Many Employees Does Alivus Life Sciences Have?
Alivus Life Sciences has 2272 employees.
What is the current trading status of Alivus Life Sciences (ALIV)?
As of 20/08/2026, Alivus Life Sciences (ALIV) is trading at a price of 1,369.00 INR, with a previous close of 1,369.00 INR. The stock has fluctuated within a day range of 1,356.30 INR to 1,416.60 INR, while its 52-week range spans from 819.00 INR to 1,418.00 INR.
What Is Alivus Life Sciences (ALIV) Price Target According to Analysts?
The average 12-month price target for Alivus Life Sciences is 1,358.75 INR, with a high estimate of 1400 INR and a low estimate of 1330 INR. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an -0.75% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.